MiNK Therapeutics, Inc. (INKT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $3.92M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $2.45M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $3.92M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $3.92M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $2.45M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $2.45M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | (m) | |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 3.92M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | 2.45M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $2.45M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.92M | (m) | $2.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $3.39M | (m) | $2.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $3.43M | (m) | $2.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.69M | (m) | $2.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $3.31M | (m) | $2.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.66M | (m) | $2.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $2.73M | (m) | $2.36M | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2024-09-30 | (m) | $2.36M | (m) | $2.39M | (m) | (m) | (m) | (m) | (m) | $2.94K | (m) |
| 2024-06-30 | (m) | $3.20M | (m) | $2.32M | (m) | (m) | (m) | (m) | (m) | $23.28K | (m) |
| 2024-03-31 | (m) | $3.49M | (m) | $2.34M | (m) | (m) | (m) | (m) | (m) | $31.60K | (m) |
| 2023-12-31 | (m) | $3.91M | (m) | $2.45M | (m) | (m) | (m) | (m) | (m) | $48.07K | (m) |
| 2023-09-30 | (m) | $4.28M | (m) | $2.27M | (m) | (m) | (m) | (m) | (m) | $63.98K | (m) |
| 2023-06-30 | (m) | $4.89M | (m) | $2.33M | (m) | (m) | (m) | (m) | (m) | $79.34K | (m) |
| 2023-03-31 | (m) | $6.00M | (m) | $2.49M | (m) | (m) | (m) | (m) | (m) | $94.18K | (m) |
| 2022-12-31 | (m) | $5.82M | (m) | $2.62M | (m) | (m) | (m) | (m) | (m) | $108.50K | (m) |
| 2022-09-30 | (m) | $5.17M | (m) | $2.09M | (m) | (m) | (m) | (m) | (m) | $58.28K | (m) |
| 2022-06-30 | (m) | $4.79M | (m) | $2.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $3.73M | (m) | $5.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.00M | (m) | $5.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.65M | (m) | $5.38M | (m) | (m) | (m) | (m) | (m) | $27.54K | (m) |
| 2020-12-31 | (m) | $3.14M | (m) | $5.69M | (m) | (m) | (m) | (m) | (m) | $383.06K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |